ReviewLife (Basel, Switzerland)2023
Pharmacological Activities of Mogrol: Potential Phytochemical against Different Diseases.
Review in Life (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Exploring the role of the NLRP3 Inflammasome in polycystic ovary syndrome: therapeutic potential of herbal medicines.Journal of ovarian research · 2026Review
- Mogrosides as Dual-Function Sweeteners: A Comprehensive Review of Extraction, Metabolism, Antidiabetic Mechanisms, and Food Applications.Nutrients · 2026Review
- Immune-Enhancement Effects of 6-Methoxykaempferol on Cyclophosphamide-Induced Immunosuppression via Improving Antioxidant Enzyme Expression, NF-κB and MAPK Signaling, and Modulating Gut Microbiome.Antioxidants (Basel, Switzerland) · 2026Article
- A Review onPlants (Basel, Switzerland) · 2026Review
- Nobiletin Attenuates Adipogenesis and Promotes Browning in 3T3-L1 Adipocytes Through Exosomal miRNA-Mediated AMPK Activation.Current issues in molecular biology · 2025Article
- Exploring the potential mechanisms of anti-pulmonary fibrosis effects of Luo Han Guo via network pharmacology, molecular docking, and experimental validation.Scientific reports · 2025Article
- Trifolirhizin: A Phytochemical with Multiple Pharmacological Properties.Molecules (Basel, Switzerland) · 2025Review
- Mogrol Regulates the Expression of ATPase Na+/K+ Transport Subunit 3, Inhibits Cardiomyocyte Apoptosis, and Plays a Protective Role Against Myocardial Infarction.Drug design, development and therapy · 2025Article
- Biological Properties and Phytochemicals of Multipurpose Tree PlantMolecules (Basel, Switzerland) · 2024Review
- The Bioactivity and Phytochemicals ofInternational journal of molecular sciences · 2024Review
- Pharmacological Properties of Shionone: Potential Anti-Inflammatory Phytochemical against Different Diseases.Molecules (Basel, Switzerland) · 2023Review
- Plant-Derived Natural Products and Their Biomedical Properties: Recent Advances and Future Directions.Life (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Recently, mogrol has emerged as an important therapeutic candidate with multiple potential pharmacological properties, including neuroprotective, anticancer, anti-inflammatory, antiobesity, antidiabetes, and exerting a protective effect on different organs such as the lungs, bone, brain, and colon. Pharmacokinetic studies also highlighted the potential of mogrol as a therapeutic. Studies were also conducted to design and synthesize the analogs of mogrol to achieve better activities against different diseases. The literature also highlighted the possible molecular mechanism behind pharmacological activities, which suggested the role of several important targets, including AMPK, TNF-α, and NF-κB. These important mogrol targets were verified in different studies, indicating the possible role of mogrol in other associated diseases. Still, the compilation of pharmacological properties, possible molecular mechanisms, and important targets of the mogrol is missing in the literature. The current study not only provides the compilation of information regarding pharmacological activities but also highlights the current gaps and suggests the precise direction for the development of mogrol as a therapeutic against different diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.